aflibercept Side Effects
Also known as: Eylea
Analysis of 29,874 adverse event reports submitted to the FDA from 2007 to 2025.
Total Reports
29,874
Death-Related
8,845
29.6% of reports
Hospitalizations
3,872
13.0% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 8,845 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 7,846 |
| OFF LABEL USE | 123 |
| MYOCARDIAL INFARCTION | 95 |
| CEREBROVASCULAR ACCIDENT | 71 |
| DIARRHOEA | 71 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 60 |
| NEOPLASM MALIGNANT | 47 |
| PNEUMONIA | 47 |
| DISEASE PROGRESSION | 44 |
| RENAL FAILURE | 43 |
| SEPSIS | 38 |
| ASTHENIA | 37 |
| FATIGUE | 37 |
| FALL | 36 |
| VOMITING | 34 |
| NEUTROPENIA | 33 |
| ANAEMIA | 31 |
| DRUG INEFFECTIVE | 31 |
| HYPERTENSION | 30 |
| DYSPNOEA | 29 |
Reactions in Hospitalization Reports
Top reactions in 3,872 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| HOSPITALISATION | 309 |
| DIARRHOEA | 214 |
| ENDOPHTHALMITIS | 214 |
| VISUAL IMPAIRMENT | 200 |
| OFF LABEL USE | 166 |
| FALL | 162 |
| CEREBROVASCULAR ACCIDENT | 152 |
| BLINDNESS | 144 |
| HYPERTENSION | 141 |
| EYE PAIN | 133 |
| ASTHENIA | 120 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 113 |
| PNEUMONIA | 112 |
| VISION BLURRED | 111 |
| VOMITING | 109 |
| MALAISE | 108 |
| MYOCARDIAL INFARCTION | 108 |
| VISUAL ACUITY REDUCED | 107 |
| PYREXIA | 106 |
| DYSPNOEA | 99 |
Nearby — Related Medications
What the FAERS Data Reveals About aflibercept Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 29,874 voluntary reports linked to aflibercept and its brand equivalents (Eylea), spanning 2007 through 2025. Of those, 8,845 (29.6%) listed death as an outcome and 3,872 (13.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 51% were female and 48% male; age distribution skews toward 75+, with 2,827 reports in that bracket. The single most reported reaction is death with 7,853 submissions, followed by visual impairment and off label use.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.